Skip to main content
Premium Trial:

Request an Annual Quote

BioTrove and Schering-Plough Expand Drug-Discovery Collaboration

NEW YORK, Dec. 6 (GenomeWeb News) - BioTrove has expanded its lead discovery collaboration with Schering-Plough Research Institute, the research arm of Schering-Plough, the company said today.


Under the terms of the collaboration, BioTrove will use its RapidFire lead-discovery service for assay development and high-throughput screening on an undisclosed number of targets identified by Schering-Plough.


RapidFire is a mass spectrometry-based technology that enables the high-throughput screening of biochemical assays, BioTrove said. The use of mass spectrometry allows for label-free screening of challenging and intractable drug targets using native substrates, the company said.


Financial terms were not disclosed.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.